S1PR1 and myeloid sarcoma: To date there are no pharmacological agents of which we are aware that operate jointly or exclusively at both S1PR-1 and S1PR-2 under investigation as potential medications for MS, yet the importance of regulating astrocyte proliferation and astrogliosis would be reasons enough to examine agents that can synergistically modulate both receptor subsets.